Umeh CA, Maoz H, Obi J, Dakoria R, Patel S, Maity G, Barve P. Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation. World J Cardiol 2023; 15(9): 427-438 [PMID: 37900264 DOI: 10.4330/wjc.v15.i9.427]
Corresponding Author of This Article
Heather Maoz, MD, Doctor, Internal Medicine, Hemet Global Medical Center, 1117 E. Devonshire Ave., Hemet, CA 92543, United States. heathermaoz@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Sep 26, 2023; 15(9): 427-438 Published online Sep 26, 2023. doi: 10.4330/wjc.v15.i9.427
Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation
Chukwuemeka A Umeh, Heather Maoz, Jessica Obi, Ruchi Dakoria, Smit Patel, Gargi Maity, Pranav Barve
Chukwuemeka A Umeh, Heather Maoz, Jessica Obi, Ruchi Dakoria, Smit Patel, Gargi Maity, Pranav Barve, Internal Medicine, Hemet Global Medical Center, Hemet, CA 92543, United States
Author contributions: Umeh CA, Maoz H, Obi J, Dakoria R, Patel S, Maity G and Barve P conceptualized and revised the study design; Umeh CA analyzed the data; Maoz H, Umeh CA, Obi J, Dakoria R, Patel S, and Maity G, wrote the first draft of the paper; Barve P and Umeh CA, reviewed and revised the paper; Maoz H led and coordinated the research and writing of the manuscript; Barve P and Umeh CA supervised the project; all authors have read and approved the final manuscript.
Institutional review board statement: The WIRB-Copernicus Group (WCG) institutional review board (IRB) approved the study. IRB approval number: 13410516.
Informed consent statement: Our study was a retrospective observational study which used medical records for data acquisition and analysis and thus does not require informed consent from subjects.
Conflict-of-interest statement: None to declare.
Data sharing statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Heather Maoz, MD, Doctor, Internal Medicine, Hemet Global Medical Center, 1117 E. Devonshire Ave., Hemet, CA 92543, United States. heathermaoz@gmail.com
Received: April 21, 2023 Peer-review started: April 21, 2023 First decision: June 19, 2023 Revised: July 12, 2023 Accepted: August 17, 2023 Article in press: August 17, 2023 Published online: September 26, 2023 Processing time: 152 Days and 16.4 Hours
Core Tip
Core Tip: Myocarditis from direct viral injury or related to angiotensin-converting enzyme (ACE) II downregulation with subsequent hyperactivity of the renin-angiotensin-aldosterone system plays an essential role in troponin elevation in coronavirus disease 2019 (COVID-19) patients. However, the effect of antiviral medications and steroids used to treat viral myocarditis has not been well-studied in patients with elevated troponins, which this study sought to address. We found no significant difference in survival rates in COVID-19 patients with elevated troponin that received remdesivir, dexamethasone, or ACE inhibitors vs those that did not. The implication for practice is that treatment with various medications that could be beneficial in viral myocarditis did not show any mortality benefit in our study for COVID-19 patients with troponin elevation.
